{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T17:56:09Z","timestamp":1648576569462},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00105-018-4353-9","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T07:20:16Z","timestamp":1549005616000},"page":"131-141","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Raynaud-Ph\u00e4nomen"],"prefix":"10.1007","volume":"70","author":[{"given":"Christian","family":"Drerup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Ehrchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"4353_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1024\/0301-1526\/a000661","volume":"46","author":"J Belch","year":"2017","unstructured":"Belch J, Carlizza A, Carpentier PH et\u00a0al (2017) ESVM guidelines\u2014the diagnosis and management of Raynaud\u2019s phenomenon. VASA 46:413\u2013423","journal-title":"VASA"},{"key":"4353_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMra1507638","volume":"375","author":"FM Wigley","year":"2016","unstructured":"Wigley FM, Flavahan NA (2016) Raynaud\u2019s phenomenon. N\u00a0Engl J Med 375:556\u2013565","journal-title":"N Engl J Med"},{"key":"4353_CR3","doi-asserted-by":"publisher","first-page":"e006389","DOI":"10.1136\/bmjopen-2014-006389","volume":"5","author":"R Garner","year":"2015","unstructured":"Garner R, Kumari R, Lanyon P et al (2015) Prevalence, risk factors and associations of primary Raynaud\u2019s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open 5:e6389","journal-title":"BMJ Open"},{"key":"4353_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fphar.2016.00438","volume":"7","author":"MM Fardoun","year":"2016","unstructured":"Fardoun MM, Nassif J, Issa K et\u00a0al (2016) Raynaud\u2019s phenomenon: a brief review of the underlying mechanisms. Front Pharmacol 7:438","journal-title":"Front Pharmacol"},{"key":"4353_CR5","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","volume":"73","author":"T Minier","year":"2014","unstructured":"Minier T, Guiducci S, Bellando-Randone S et al (2014) Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a\u00a0pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 73:2087\u20132093","journal-title":"Ann Rheum Dis"},{"key":"4353_CR6","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1002\/art.24038","volume":"58","author":"M Koenig","year":"2008","unstructured":"Koenig M, Joyal F, Fritzler MJ et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a\u00a0twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58:3902\u20133912","journal-title":"Arthritis Rheum"},{"key":"4353_CR7","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"key":"4353_CR8","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1136\/annrheumdis-2012-201536","volume":"72","author":"LK Hummers","year":"2013","unstructured":"Hummers LK, Dugowson CE, Dechow FJ et al (2013) A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a\u00a0novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Ann Rheum Dis 72:1962\u20131967","journal-title":"Ann Rheum Dis"},{"key":"4353_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd000467.pub2","author":"F Rirash","year":"2017","unstructured":"Rirash F, Tingey PC, Harding SE et\u00a0al (2017) Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.cd000467.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4353_CR10","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","volume":"72","author":"M Roustit","year":"2013","unstructured":"Roustit M, Blaise S, Allanore Y et al (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud\u2019s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72:1696\u20131699","journal-title":"Ann Rheum Dis"},{"key":"4353_CR11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","volume":"75","author":"E Hachulla","year":"2016","unstructured":"Hachulla E, Hatron PY, Carpentier P et al (2016) Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 75:1009\u20131015","journal-title":"Ann Rheum Dis"},{"key":"4353_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","volume":"40","author":"B Coleiro","year":"2001","unstructured":"Coleiro B, Marshall SE, Denton CP et\u00a0al (2001) Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxf) 40:1038\u20131043","journal-title":"Rheumatology (Oxf)"},{"key":"4353_CR13","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","volume":"42","author":"M Dziadzio","year":"1999","unstructured":"Dziadzio M, Denton CP, Smith R et al (1999) Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a\u00a0fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646\u20132655","journal-title":"Arthritis Rheum"},{"key":"4353_CR14","first-page":"503","volume":"19","author":"R Scorza","year":"2001","unstructured":"Scorza R, Caronni M, Mascagni B et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503\u2013508","journal-title":"Clin Exp Rheumatol"},{"key":"4353_CR15","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00105-003-0578-2","volume":"54","author":"G Bali","year":"2003","unstructured":"Bali G, Aberer E (2003) Iloprost therapy in systemic sclerosis. Hautarzt 54:845\u2013851","journal-title":"Hautarzt"},{"key":"4353_CR16","first-page":"381","volume":"15","author":"S Ceru","year":"1997","unstructured":"Ceru S, Pancera P, Sansone S et al (1997) Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis. Clin Exp Rheumatol 15:381\u2013385","journal-title":"Clin Exp Rheumatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4353-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-018-4353-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4353-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T09:32:40Z","timestamp":1580722360000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-018-4353-9"}},"subtitle":["Praktisches Management durch den Dermatologen"],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4353"],"URL":"https:\/\/doi.org\/10.1007\/s00105-018-4353-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"22 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Drerup und J.\u00a0Ehrchen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht m\u00fcndigen Patienten liegt die Einwilligung eines Erziehungsberechtigten oder des gesetzlich bestellten Betreuers vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}